Skip to main content
C

CHINA RESOURCES JIANGZHONG PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 600750 ISIN · CNE000000M80 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,747 across all filing types
Latest filing 2026-05-25 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 600750

About CHINA RESOURCES JIANGZHONG PHARMACEUTICAL CO.,LTD

China Resources Jiangzhong Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of over-the-counter (OTC) medicines, traditional Chinese medicine (TCM), and health supplements. The company is a recognized leader in the gastrointestinal health sector, primarily known for its flagship product, Jiangzhong Jianwei Xiaoshi Tablets, a widely used digestive aid. Its product portfolio also includes throat care solutions such as Jiangzhong Cao Shanhu Lozenges and various nutritional supplements. By integrating traditional herbal knowledge with modern pharmaceutical technology, the company focuses on providing healthcare solutions for digestive wellness, respiratory health, and general preventive care. The enterprise maintains a strong emphasis on quality control and innovation within the consumer healthcare market.

Recent filings

Filing Released Lang Actions
华润江中关于2021年限制性股票激励计划预留授予部分第三个解除限售期解锁暨上市的公告
Share Issue/Capital Change Classification · 80% confidence The document is a corporate announcement detailing the third vesting/unlocking of restricted shares under the 2021 stock incentive plan, including the listing date, number of shares to be released (139,924 shares), board approvals, and changes in share capital structure. It is not a full financial report but a notice of share issuance/unlocking (capital change). Under FinancialReports taxonomy, this falls under “Share Issue/Capital Change” (SHA).
2026-05-25 Chinese
华润江中董事会薪酬与考核委员会对关于回购注销部分激励对象已获授但尚未解除限售的限制性股票事项的核查意见
Transaction in Own Shares Classification · 93% confidence The document is a formal notice from the Board’s Compensation and Assessment Committee regarding the repurchase and cancellation of 25,000 restricted shares under the company’s equity incentive plan. This is a transaction where the company buys back its own shares, fitting the definition of a share repurchase announcement. Therefore, it should be classified as a Transaction in Own Shares (POS).
2026-05-15 Chinese
华润江中关于回购注销部分限制性股票通知债权人的公告
Transaction in Own Shares Classification · 95% confidence The document is a formal board announcement notifying creditors of the company’s repurchase and cancellation of restricted shares, resulting in a reduction of registered capital. It details the terms, legal basis, and creditor filing procedures for a share buyback and cancellation. This fits the definition of a Transaction in Own Shares (share repurchase) rather than an earnings release or broader capital structure update.
2026-05-15 Chinese
国浩律师（上海）事务所关于华润江中药业股份有限公司第二期限制性股票激励计划回购注销部分限制性股票事宜的法律意见书
Transaction in Own Shares Classification · 92% confidence The document is a law firm’s legal opinion letter specifically addressing the company’s repurchase and cancellation of restricted shares under its incentive plan. It is not an annual or interim financial report, nor a management or earnings announcement. It details the mechanics of a share repurchase transaction, fitting the definition of “Transaction in Own Shares.” Therefore, it should be classified under POS (Transaction in Own Shares).
2026-05-15 Chinese
华润江中关于与广东华润银行开展存款业务暨关联交易的公告
Regulatory Filings Classification · 75% confidence The document is a formal announcement by 华润江中药业 about entering into a related‐party deposit arrangement with Guangdong 华润银行, including background, approvals, pricing, and terms. It is not a financial report (no consolidated statements), not a proxy or dividend notice, and not an executive certification. There is no dedicated category for related‐party transactions, so it falls under the generic Regulatory Filings (RNS) category.
2026-05-15 Chinese
华润江中第十届董事会第十五次会议决议公告
Regulatory Filings Classification · 82% confidence The document is an announcement of the board of directors’ resolutions (第十届董事会第十五次会议决议公告), detailing proposals approved by the board (remuneration management rules, audit appointment, restricted share repurchase, related‐party deposit business, etc.). It is not the actual full financial report, an AGM or shareholder vote result, nor a change in board members or a proxy statement. This type of announcement of board meeting decisions is a general regulatory filing. Therefore, it falls under the “Regulatory Filings” fallback category (RNS).
2026-05-15 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.